Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Gets NY State Permit for microRNA Tests

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics has received a clinical laboratory permit from the New York State Department of Health allowing the firm to offer its microRNA-based tests to physicians and patients in the state.

The firm currently sells three tests — the miRview meso, miRview mets, and miRview squamous — that are run at its own Philadelphia-based CAP-accredited, CLIA-certified lab.

The miRview meso test differentiates lung cancer from mesothelioma; miRview mets is designed to determine the source of cancers of unknown primary origin; and miRview squamous is designed to differentiate squamous from non-squamous non-small cell lung cancer.

Rehovot, Israel-based Rosetta said that it also is working with the NYS DOH to gain approval for its second-generation versions of the tests.

Rosetta Genomics President and CEO Kenneth Berlin noted that the firm's tests are now available to residents of all 50 states in the US.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.